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metal stents and first ‑generation drug ‑eluting 
stents (DESs), stent length was identified as 
a risk factor for clinical device failure, mostly 
INTRODUCTION Coronary lesion length deter‑
mines the length of stent(s) needed in percutane‑
ous coronary revascularization (PCI). With bare 
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ABSTRACT
INTRODUCTION Long and diffuse coronary lesions (LDCLs) are routinely subjected to percutaneous 
management, but long ­term clinical outcomes and complication predictors with the use of contemporary 
stents and techniques remain undetermined.
OBJECTIVES The aim of the study was to address long ­term effects of percutaneous management of 
LDCLs, using contemporary devices and optimization techniques.
PATIENTS AND METHODS Long and diffuse coronary lesion was defined as a lesion requiring an implanta­
tion of 30 mm or longer total stent(s) length (TSL) into one coronary artery (bail outs excluded). There 
were 290 LDCL interventions with the use of newer generation drug ­eluting stents (DESs; cobalt chro­
mium everolimus– or zotarolimus–eluting stents) performed between January 2013 and January 2016.
RESULTS The mean (SD) TSL was 55.5 (16.8) mm. The use of intravascular ultrasound / optical coher­
ence tomography was 17.1%, rotablation, 6.9%, and noncompliant balloon, 88.9%. The median (range) 
follow ­up duration was 831 (390–1373) days. All ­cause mortality and cardiac death rates were 11.7% 
and 6.9%, respectively. The myocardial infarction (MI) rate was 6.6%, including target ­vessel MI in 4.1%. 
The rate of clinically ­driven repeat revascularization was 13.8%, and of definite or probable LDCL stent 
thrombosis, 7.2%. Overall patient ­oriented adverse event rate (any death, MI, or repeat revascularization) 
was 25.5%, and device ­oriented rate (cardiac death, target vessel ­MI, or target lesion restenosis), 13.4%. 
Adverse outcome predictors were chronic kidney disease, acute coronary syndrome as an indication for 
the procedure, chronic heart failure with reduced left ventricular ejection fraction, multivessel disease, 
and coexisting peripheral artery disease, but not lesion ­related factors, such as bifurcation, calcification, 
chronic total occlusion, or TSL.
CONCLUSIONS Adverse outcomes following contemporary LDCL management using newer generation 
DESs in routine clinical practice are associated with clinical patient characteristics rather than lesion 
characteristics or TSL. We identified high ­risk patient cohorts that may benefit from enhanced surveillance.
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(POCE), which is a composite of all ‑cause mor‑
tality, any MI, and any repeat revascularization.
Angiograms were analyzed and assessed by 2 
independent operators, with any discrepancies 
resolved by consensus.
Procedures Percutaneous coronary intervention 
was performed according to guidelines current 
at the time of the study.7 The implanted devices 
were newer‑generation DESs. Procedure strategy, 
including predilation, advanced imaging, particu‑
lar stent use (EES or ZES), and optimization tech‑
niques were at the operator’s discretion.
The following factors were analyzed as poten‑
tially affecting the outcomes: target vessel, num‑
ber of stented vessels (including the LDCL), tar‑
get lesion heavy calcifications defined as multiple 
opacifications surrounding the lumen in at least 
2 projections, involvement of rotational ather‑
ectomy, chronic total occlusion (CTO) as the tar‑
get lesion, major bifurcation(s) involvement (side 
branch of ≥1.5 mm in diameter), TSL, number of 
stents per lesion, use of kissing balloons tech‑
nique, distal embolization, major side branch 
occlusion, and final flow in the target vessel in 
the Thrombolysis in Myocardial Infarction scale.
After the procedure, all patients were pre‑
scribed dual antiplatelet therapy (DAPT): ace‑
tylsalicylic acid plus clopidogrel or acetylsali‑
cylic acid plus ticagrelor (none of the patients 
used prasugrel) and other medications, includ‑
ing typically a statin, β ‑blocker, and angiotensin‑
‑converting enzyme inhibitor or angiotensin re‑
ceptor blocker, as per current European Society of 
Cardiology (ESC) guidelines on the management 
of stable CAD. The duration of DAPT was based 
on the clinical presentation of CAD, according 
to ESC guidelines. Statin treatment was aimed 
to achieve guideline ‑recommended target low‑
‑density lipoprotein cholesterol levels.
Follow ‑up Patients were scheduled for routine 
clinical follow ‑up in a local outpatient clinic 4 to 
8 weeks after the index procedure and annually 
thereafter. A total of 212 patients (73.1%) attend‑
ed the final out patient clinic follow ‑up visit. An‑
other 55 patients (19.0%) were not able to attend 
due to logistic reasons (travel distance, satisfac‑
tory general practitioner care), and thus our final 
follow ‑up evaluation was performed via physician 
phone ‑call interview. Medical documentation re‑
garding the presence of any definite or suspect‑
ed endpoint was reviewed. For the remaining 23 
patients, who were lost to follow up (7.9%), only 
the vital status was obtained via a national elec‑
tronic database. If an endpoint was registered, 
the length of follow ‑up analyzed was the time that 
elapsed from the day of the procedure to the day 
when the endpoint occurred. The final follow ‑up 
for patients with no registered endpoints varied 
depending on the time of scheduled outpatient 
clinic visits. The final phone calls for patients out‑
side the care of our out patient clinic were made 
between January 16 and February 9, 2017, with 
due to increased restenosis and stent thrombo‑
sis rates, as well as a need for repeat revascular‑
ization.1,2 Clinical implementation of newer gen‑
eration DES (everolimus ‑eluting stent [EES] or 
zotarolimus ‑eluting stent [ZES]) has led to a sig‑
nificant improvement in long ‑term outcomes.3,4 
Although long stent(s) use is part of routine PCI 
today, the effect of total stent(s) length (TSL) 
used to treat long and diffuse coronary lesions 
(LDCLs) on the risk of adverse event remains 
undetermined.
Our study was designed to evaluate long ‑term 
clinical outcomes and predictors of complications 
in newer‑generation DESs used to treat LDCLs in 
routine clinical practice of PCI.
PATIENTS AND METHODS Study design This was 
a single ‑center retrospective study. Long and dif‑
fuse coronary lesion was defined as a lesion re‑
quiring a planned implantation of TSL of 30 mm 
or longer into a single coronary artery. We in‑
cluded consecutive patients with LDCL interven‑
tions performed between January 2013 and Jan‑
uary 2016. We excluded bare metal stent use (rare 
in LDLC, 1.4%) and focused on newer‑generation 
DESs (cobalt chromium EES or ZES) used to treat 
LDCLs in 290 patients with stable coronary ar‑
tery disease (CAD) or acute coronary syndrome 
(ACS; including ST ‑segment elevation myocardi‑
al infarction [STEMI], non–ST ‑segment elevation 
myocardial infarction, and unstable angina). Pa‑
tients presenting with cardiogenic shock or bail‑
outs were excluded. As per standard at our center, 
elective patients with multivessel disease (MVD) 
or lesions in the left main (LM) or proximal left 
anterior descending artery (LAD) were consult‑
ed and referred by the heart team.
We analyzed the  effect of procedure ‑ and 
patient ‑related factors on the incidence of the fol‑
lowing Academic Research Consortium (ARC) 
endpoints5: all ‑cause mortality, cardiac death, any 
myocardial infarction (MI), target lesion–related 
MI, target lesion restenosis (TLR), stent throm‑
bosis, and repeat revascularization. Any death 
without a definite noncardiac cause was consid‑
ered a cardiac death. Myocardial infarction was 
diagnosed according to the universal definition.6 
An MI was treated as target lesion ‑related, unless 
there was clear evidence to the contrary. An event 
was coded as TLR when an angiographically con‑
firmed lesion (50% or greater) was found within 
the primarily stented section of the vessel, and 
the patient had clinical symptoms or functional 
evidence of ischemia. Definite, probable, or pos‑
sible, as well as subacute, acute, late, and very 
late stent thromboses were coded in accordance 
with the ARC.5 An intervention was coded as a re‑
peat revascularization in cases that had not been 
planned beforehand as part of the treatment. We 
also analyzed composite endpoints in accordance 
with the ARC guidelines. We defined a device‑
‑oriented composite endpoint (DOCE) composed 
of cardiac death, target vessel ‑related MI and TLR, 
as well as a patient ‑oriented composite endpoint 
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Procedures and devices The  mean (SD) TSL 
was 55.5 (16.8) mm. For the majority of LDCLs, 
2 stents were used (217 procedures, 74.8%). 
The EES (Xience, Abbott, Santa Clara, Califor‑
nia, United Statrs) was used in 159 procedures 
(54.8%), the ZES (Resolute Integrity, Medtron‑
ic, Minneapolis, Minnesota, United States) in 
128 (44.1%), and a combination of EES and ZES 
was implanted in 3 patients (1%). The LDCL was 
predominantly located in the right coronary ar‑
tery (40.7%) and LAD (39.7%). The left main ar‑
tery was involved in 26 of the cases (9%), most 
of which were combined LM/LAD lesions. Over‑
lapping stents were used in 83.1% of patients; 
a major bifurcation (side branch no smaller than 
1.5 mm in diameter) was present in 41.8%, and 
the kissing technique was employed in 22% of 
the procedures. A CTO accounted for the long 
lesion in 20% of the cases. Heavily calcified le‑
sions were present in 45.2% of the cases, with 
rotational atherectomy being used in 6.9% of 
all PCIs (heavily calcified lesions, 15.3%). A sub‑
stantial number of patients had MVD (29.7%, 
with 13.8% postcoronary artery bypass grafting 
[CABG]). The SYNTAX score ranged from 2 to 44, 
with a median of 16. Distal vessel embolization or 
side branch occlusion occurred in 6.2% of the cas‑
es. A final Thrombolysis in Myocardial Infarction 
grade 3 flow was achieved in 96.2% of the proce‑
dures. Procedural details are presented in TABLE 2.
Follow ‑up The median follow ‑up was 831 days 
(range, 390–1373; interquartile range, 459). 
Death occurred in 34 patients (11.7%), with 
the underlying cardiac cause in 21 (6.9%). A to‑
tal of 19 patients had MI (6.6%), and in 12 cases 
(4.1%), the event was related to the target vessel. 
Repeat revascularization was required 45 times 
in 40 patients (13.8%), and target ‑vessel revas‑
cularization occurred in 18 of the cases (6.2%). 
The majority of those revascularizations was re‑
peated PCI. Restenosis within the target vessel 
was confirmed in 9 cases (3.1%). In 9 patients 
(3.1%), a target lesion definite stent thrombosis 
was established, and in 12 (4.1%) the ARC cri‑
teria for probable stent thrombosis were met. 
Of the episodes of definite stent thrombosis 3 
were acute, 3 subacute, 2 late, and 1 very late. In 
1 case of subacute stent thrombosis, the under‑
lying cause was noncompliance to DAPT. In pa‑
tients on acetylsalicylic acid plus ticagrelor ther‑
apy (3.8%), neither definite nor probable stent 
thrombosis occurred.
The DOCE occurred in 39 patients (13.4%) 
whereas the POCE in 74 (25.5%). Follow ‑up data 
are presented in TABLE 3.
Results of univariate and multivariate analysis In 
the univariate analysis (TABLE 4), the strongest pre‑
dictor of DOCE was CKD (P = 0.002, Supplemen‑
tary material, Figure S1). In particular, a 1 ‑point 
decrease in glomerular filtration rate was associ‑
ated with a 2% increase in the risk of DOCE. Oth‑
er factors related to DOCE were ACS (P = 0.01; 
a final vital status check performed on February 
11 to 13, 2017.
This study was approved by an institutional re‑
view board. Patients provided written informed 
consent to participate in the study.
Statistical analysis The Shapiro–Wilk test was 
used to check for normal distribution of the vari‑
ables. The results were presented as the mean 
(SD) when the distribution was normal, or as 
median and interquartile range when the distri‑
bution differed from normal. Potential effects of 
patient ‑ and procedure ‑related factors on the inci‑
dence of composite endpoints were evaluated us‑
ing the univariate and multivariate Cox propor‑
tional hazard models. Multivariate models were 
estimated with the backward step ‑wise selection 
procedure with the variables with a P value of less 
than 0.1 from the univariate analysis as the ini‑
tial list. Proportionality of hazards was evaluat‑
ed by the Kaplan–Meier analysis and checking 
the dependence of residuals on time. In the final 
models, a P value of less than 0.05 was consid‑
ered significant.
RESULTS Patients The mean (SD) age of pa‑
tients at the time of the index procedure was 67.0 
(10.6) years. Men constituted 71.7% of the study 
group. The representation of risk factors for CAD 
was typical (TABLE 1).
TABLE 1 Basic patient data
Parameter Value
Age, y, mean (SD) 67 (10.6)
BMI, kg/m2, mean (SD) 28.2 (4.5)
LVEF, %, mean (SD) 43.8 (15)
GFR on admission, ml/min/1.73 m2, mean (SD) 68.9 (20.1)
Total cholesterol / LDL­C, mmol/l, mean (SD) 4.4/2.7 (1.3/1)
Male sex 208 (71.7)
Hypertension 265 (91.4)
Lipid disorders 254 (87.6)
Diabetes / diabetes with insulin use 101/37 (34.8/12.8)
Smoking 112 (38.6)
Obesity 94 (32.4)
Chronic kidney insufficiency 44 (15.2)
History of stroke or TIA 23 (7.9)
Peripheral artery disease 27 (9.3)
History of ACS 123 (42.4)
History of PCI / CABG 90/40 (31/13.8)
MVD 86 (29.7)
ACS as indication for procedure 157 (54.1)
STEMI / NSTEMI / UA 54/83/20 (18.6/28.6/6.9)
Data are presented as number (percentage) unless otherwise indicated.
Abbreviations: ACS, acute coronary syndrome; BMI, body mass index, CABG, coronary 
artery bypass grafting; GFR, glomerular filtration rate; LDL­C, low­density lipoprotein 
cholesterol; LVEF, left ventricular ejection fraction; MVD, multivessel disease; NSTEMI, 
non–ST ­segment elevation myocardial infarction; PCI, percutaneous coronary 
intervention; STEMI, ST ­segment elevation myocardial infarction; TIA, transient 
ischemic attack; UA, unstable angina
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The multivariate analysis (TABLE 5) showed that 
only coexistent PAD was an independent predic‑
tor of DOCE. For POCE, ACS as the clinical indi‑
cation, CHF, and single ‑vessel disease (protective 
role in the case of the latter) remained significant 
after adjustment for other factors.
Importantly, neither TSL nor other procedur‑
al factors influenced any of the endpoints. There 
were no differences in outcomes between EESs 
and ZESs.
DISCUSSION The main finding of this study 
is that in contemporary routine management 
of LDCL, PCI with the use of newer‑generation 
DESs as well as imaging and optimization tech‑
niques, lesion and procedural factors (including 
TSL) do not determine long ‑term outcomes. De‑
spite guideline ‑indicated medical management, 
patient‑related factors such as MVD, CKD, CHF, 
and PAD remain risk factors for long ‑term ad‑
verse events.
Traditionally, LDCLs have been considered to 
be associated with an increased risk of complica‑
tions following PCI.1,2 Still, specific data on LDCL 
PCI in contemporary clinical practice are lacking. 
A subanalysis of the RESOLUTE all ‑comers (Ran‑
domized Comparison of a Zotarolimus ‑Eluting 
Stent with an Everolimus ‑Eluting Stent for Percu‑
taneous Coronary Intervention) trial, focused on 
complex coronary lesions as compared with sim‑
ple ones, indicated no differences in 1 ‑year clini‑
cal outcomes irrespective of the particular newer‑
generation DES type. In that study, the definition 
of complex patient/lesions involved a number of 
patient ‑related and angiographic factors includ‑
ing lesion length with the cutoff value of 27 mm 
as one of the complexity criteria (only 1 was re‑
quired to meet the complexity definition).3 A sub‑
study of the prospective, randomized, multicenter 
CENTURY II (Clinical Evaluation of New Terumo 
Drug‑Eluting Coronary Stent System in the Treat‑
ment of Patients with Coronary Artery Disease ) 
trial has shown very satisfactory short ‑term re‑
sults in patients with long lesions treated with 
bioresorbable polymer sirolimus ‑eluting stent 
or EES.8 This study, however, dealt with a differ‑
ent population than ours. The mean lesion length 
was approximately 33 mm, and there was a 3 ‑fold 
smaller number of patients with STEMI. Although 
a significant percentage of patients in the CEN‑
TURY II substudy had MVD, the mean SYNTAX 
score was lower and fewer patients were post‑
‑CABG. Furthermore, the percentage of patients 
with a multivessel PCI was 2 ‑fold higher in our 
study, all of which probably influenced the results. 
Recently, the results of a single ‑center, retro‑
spective study on 71 patients with extremely long 
lesions (60–106 mm) with the use of ZES and bi‑
olimus A9 ‑eluting stents have been published, 
also showing good clinical outcomes.9 Still, lesion 
length was not sufficiently evaluated as a sepa‑
rate risk factor, and thus the impact of this vari‑
able on long ‑term PCI outcome with newer‑gen‑
eration DES remains unknown.
Supplementary material, Figure S2), MVD (P = 
0.03; Supplementary material, Figure S3), and 
the coexistence of peripheral artery disease (PAD) 
(P = 0.046, Supplementary material, Figure S4). 
The single procedure ‑related variable with an in‑
fluence on DOCE was CTO as the target lesion (P = 
0.01; Supplementary material, Figure S5). Device‑
‑oriented composite endpoints occurred less fre‑
quently in patients with CTO than in those with 
non ‑CTO target lesion. 
For POCE, the strongest predictor was CKD 
(P = 0.002; Supplementary material, Figure S6) 
and ACS as the clinical indication (P = 0.002; Sup‑
plementary material, Figure S7). A 1 ‑point rise in 
the glomerular filtration rate decreased the risk 
of POCE by 1.9%. This was followed by MVD (P = 
0.01; Supplementary material, Figure S8), PAD (P 
= 0.03; Supplementary material, Figure S9), and 
congestive heart failure (CHF) (P = 0.04; Supple‑
mentary material, Figure S10). Single ‑vessel dis‑
ease was associated with a lower risk of POCE 
(P = 0.049).
TABLE 2 Procedural characteristics
Parameter Value
Stent length, mm, mean (SD) 55.5 (16.8)
Radiation / body mass, Gy/kg, mean (SD) 0.03 (0.02)
SYNTAX score, median (min–max range) 16 (2–44)
Number of stents / lesion 1 25 (8.6)
2 217 (74.8)
3 39 (13.4)
>3 9 (3.1)
Target vessel RCA 118 (40.7)
LAD 115 (39.7)
Cx 46 (15.8)
LM 26 (9.0)
Overlap 241 (83.1)
Major bifurcation 119 (41.8)
Kissing technique 64 (22.0)
NC balloon postdilation 258 (88.9)
IVUS optimization 41 (14.1)
IVUS and / or NC balloon optimization 266 (91.7)
CTO as target lesion 58 (20.0)
Heavy calcifications 131 (45.2)
Rotational atherectomy 20 (6.9)
>1 stented vessel 140 (48.3)
Distal embolization 18 (6.2)
Side branch occlusion 18 (6.2)
Final TIMI grade 3 279 (96.2)
GP IIb/IIIa inhibitor use 11 (3.8)
P2Y12 inhibitor: clopidogrel / ticagrelor 279/11 (96.2/3.8)
Data are presented as number (percentage) unless otherwise indicated.
Abbreviations: CTO, chronic total occlusion; Cx, circumflex artery; GP, glycoprotein; 
IVUS, intravascular ultrasound; LAD, left anterior descending artery, LM, left main 
artery; NC, noncompliant; RCA, right coronary artery; TIMI, Thrombolysis in Myocardial 
Infarction
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The focus of our study was to assess the influ‑
ence of TSL of 30 mm or longer with the use of 
newer‑generation DESs in LDCL in an all ‑comer 
cohort. We found that TSL was not associated 
with the risk of peri procedural or long ‑term com‑
plications. Specifically, none of the procedural 
factors analyzed (TABLE 1) increased the risk of 
DOCE and POCE. On the other hand, a number of 
patient ‑related factors did influence the long ‑term 
results, indicating that these variables should still 
be considered. The overall number of major acute 
and / or adverse cardiovascular events (MACEs) in 
our study is comparable to that from other con‑
temporary reports.3,4
Peripheral artery disease Peripheral artery disease 
was present in 9.3% of patients, which is consis‑
tent with contemporary data reported by Midwall 
et al.10 Our analysis demonstrates a negative im‑
pact of PAD on both DOCE and POCE in patients 
with LDCL PCI. Earlier studies in PCI populations 
showed that PAD increased the risk of in ‑hospital 
MI and death, as well as cardiac and overall mor‑
tality rates in the long ‑term follow ‑up.10,11 Pa‑
tients with multilevel atherosclerosis probably 
have a larger genetic and environmental burden 
predisposing to a more dynamic development and 
progression of plaques or a less favorable vessel‑
‑wall response, hence a larger probability of TLR, 
stent thrombosis, and MI (composites of DOCE). 
On the other hand, in the case of POCE, the ef‑
fect of PAD may have been overshadowed by co‑
morbidities, as was suggested before.10,11
Kidney disease We found a significant link be‑
tween CKD and both composite endpoints. Al‑
though in ‑hospital complications in patients with 
renal failure undergoing PCI have been well de‑
scribed,12 long ‑term data are scarce and include 
a potential relationship between in ‑stent reste‑
nosis and microalbuminuria. Microalbuminuria 
is a marker of microvascular damage in CKD and 
thus a predictor of small ‑vessel damage in oth‑
er organs, implicating an associaton with worse 
final outcome.13
Indication for the procedure Acute coronary syn‑
drome appeared to be a predictor of DOCE, but 
the significance was lost in the multivariate anal‑
ysis. It was also found to be a strong predictor 
of POCE, and remained significant after adjust‑
ment for other factors in the multivariate anal‑
ysis. This outcome is consistent with the fact 
that patients with ACS represent a high ‑risk 
profile group.14
Multivessel disease versus single ‑vessel dis‑
ease Multivessel disease was found to be a pre‑
dictor of both DOCE and POCE. This is consis‑
tent with previous findings.15 However, it is 
probable that individuals with MVD who were 
referred for PCI rather than CABG were more 
likely to have multiple comorbidities, which con‑
tributed to POCE. The fact that MVD fell below 
TABLE 3 Follow ­up data
Endpoint Value
All ­cause mortality 34 (11.7)
Cardiac death 21 (6.9)
MI 19 (6.6)
MI (definitely or possibly target lesion–related) 12 (4.1)
Repeat revascularization (target and non target lesion) 40 (13.8)
PCI 39 (13.4)
CABG 6 (2.1)
Target vessel revascularization 18 (6.2)
Target lesion restenosis 9 (3.1)
Target lesion definitea thrombosis All lesions 9 (3.1)
Acute 3 (1.0)
Subacute 3 (1.0)
Late 2 (0.6)
Very late 1 (0.3)
Probablea thrombosis 12 (4.1)
Possiblea thrombosis 14 (4.8)
Definite and probable thrombosis 21 (7.2)
DOCE 39 (13.4)
POCE 74 (25.5)
Data are presented as number (percentage).
a In accordance with the Academic Research Consortium definitions
Abbreviations: DOCE, device ­oriented composite endpoint; MI, myocardial infarction; 
POCE, patient ­oriented composite endpoint; others, see TABLE 1
TABLE 4 Univariate analysis of patient­ and procedure ­related factors with 
a significant effect on endpoints
Parameter P value
DOCE POCE
Patient ­related factors
Peripheral artery disease 0.046 0.03
Chronic kidney disease 0.002 0.002
Multi ­vessel disease 0.03 0.01
Acute coronary syndrome 0.01 0.002
Chronic heart failure 0.32 0.04
Procedure ­related factors
Chronic total occlusion 0.008 0.20
Abbreviations: see TABLE 3
TABLE 5 Multivariate Cox model
Variables HR 95% CI P value
DOCE PAD 3.16 1.15–8.66 0.03
POCE CHF 2.37 1.31–4.28 0.004
ACS 1.99 1.16–3.44 0.01
Single­vessel 
disease
0.47 0.23–0.96 0.04
Abbreviations: CHF, congestive heart failure; HR, hazard ratio; PAD, peripheral artery 
disease; others, see TABLES 1 and 3
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and prefer a less aggressive approach. Based on 
a national registry from 2017 (the National Reg‑
istry of Procedures of Invasive Cardiology, not 
published), the rate of rotablation in Poland was 
only roughly 0.7% of all PCIs.
Finally, we found only 9 definite stent throm‑
boses (3.1%), 1 of which was attributable to pre‑
mature DAPT discontinuation. The remaining 8 
occurred after the standard period of DAPT use. 
The percentage of definite and probable stent 
thrombosis was rather high (7.2%). This might 
be due to the fact that a large proportion of these 
patients were admitted due to ACS (54.1%), espe‑
cially STEMI (18.6% of the whole cohort, 34.4% 
of ACS). Also, ticagrelor was prescribed only in 
3.8% of the cases, none of which presented in‑
‑stent thrombosis.
Study limitations This was a retrospective analy‑
sis. Our definition of TSL of no less than 30 mm 
does not consider overlap implantations. Howev‑
er, in cases where the overlap was present, the ac‑
tual length of the covered artery segment was 
approximately 1 to 2 mm shorter than the sum 
of stents. However, this is unlikely to have sig‑
nificantly affected our findings. TSL was deter‑
mined through operator assessment, which may 
be a source of some heterogeneity. Even though 
the analyzed data came from a large ‑volume cen‑
ter, due to the specific inclusion criteria, the sam‑
ple size was moderate, which could be a source of 
error. The median follow‑up time in this study 
was 27.7 months with a minimum of 13 months, 
which is significantly longer than the majority of 
contemporary stent studies, which routinely re‑
port 12 ‑month data.3 This was not a randomized 
study. A proportion of patients was referred by 
cardiac surgeons to our and other centers due to 
the number and severity of comorbidities. Hence, 
the analyzed population reflects day ‑to ‑day real‑
ity in the catheterization laboratory.
Conclusions This study shows that with the rou‑
tine use of newer generation of DESs and current 
optimization techniques, LDCL stenting is not as‑
sociated with an increased risk of device ‑oriented 
endpoints. Patient ‑related factors that need care‑
ful consideration when deciding on treating LDLC 
percutaneously include CKD, CHF, PAD, and MVD. 
With newer‑generation DESs used to treat LDLC, 
long ‑term clinical outcomes appear superior to 
those previously published for bare metal stents 
and first‑degeneration DESs. Time will tell wheth‑
er continued device improvements such as fully 
resorbable polymers, abluminal drug coating, or 
new‑generation bioresorbable scaffolds with stan‑
dard application of proper lesion adaptation, post‑
implantation optimization, and wider adoption 
of intracoronary imaging will further improve 
long ‑term outcomes in long lesions.
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the significance threshold in the multivariate 
analysis supports this explanation.
Chronic heart failure Chronic heart failure was 
found to increase the risk of POCE in the univar‑
iate and multivariate analyses. This is consistent 
with previous reports, where CHF was shown to 
increase both short‑ and long ‑term PCI compli‑
cations.16 This could be justified by a reduced car‑
diac reserve, higher risk of life ‑threatening ar‑
rhythmias and comorbidities, but also by more 
intricate pathophysiological mechanisms, such 
as enhanced activation of the coagulation sys‑
tem, which has been described in individuals 
with CHF.17 This could predispose to thrombotic 
events, additionally increasing the frequency of 
the assessed endpoints.
Diabetes mellitus Diabetes mellitus has been long 
known to increase the risk of coronary resteno‑
sis18,19 and MACE.9 We found that with the use 
of newer‑generation DES to treat long coronary 
lesions, diabetes mellitus did not come across 
as a risk factor of poor long ‑term outcome. This 
result may reflect the impact of improved stent 
technology, overall PCI strategy, and better glyce‑
mic control with new, more effective drugs. Still, 
this is somewhat controversial and would require 
further studies, especially to determine LDCL PCI 
outcomes in the context of the efficacy of medi‑
cal treatment of diabetes mellitus.
Procedure ‑related factors The only procedure‑
‑related factor associated with the long ‑term 
outcome of LDCL PCI was CTO as the target le‑
sion. Interestingly, patients with CTO had a sig‑
nificantly lower risk of DOCE. This could be ex‑
plained by a possibility that any restenosis or tar‑
get vessel –related MI were clinically silent due to 
well ‑developed collaterals and remained unno‑
ticed. No other procedure ‑related variables, in‑
cluding TSL, proved to predict the long‑term out‑
come in LDCL PCI. This is similar to the findings 
by Çoner et al,9 where TSL, stent diameter, and 
number of stents / vessels was also not found to 
impact the MACE rate.
In this study, the majority (91.7%) of proce‑
dures were optimized using noncompliant bal‑
loons and / or intravascular imaging. Moreover, 
6.9% of all lesions were adapted by use of rota‑
tional atherectomy. This may explain the lack of 
any significant effect of lesion length, calcifica‑
tion, or bifurcation on long ‑term outcome in our 
analysis. The disproportion between heavily cal‑
cified lesions (45.2%) and the rate of rotational 
atherectomy (6.9%) might be explained by the fact 
that most of these lesions were crossable and suf‑
ficiently adaptable with a noncompliant balloon, 
which is a first choice in accordance with the cur‑
rent ESC guidelines dedicated to revasculariza‑
tion, including rotablation.20 Although the fre‑
quency of rotablation use is growing, it is sel‑
dom used upfront, as not all operators feel com‑
pletely comfortable using rotational atherectomy 
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